Unknown

Dataset Information

0

A CNS-permeable Hsp90 inhibitor rescues synaptic dysfunction and memory loss in APP-overexpressing Alzheimer's mouse model via an HSF1-mediated mechanism.


ABSTRACT: Induction of neuroprotective heat-shock proteins via pharmacological Hsp90 inhibitors is currently being investigated as a potential treatment for neurodegenerative diseases. Two major hurdles for therapeutic use of Hsp90 inhibitors are systemic toxicity and limited central nervous system permeability. We demonstrate here that chronic treatment with a proprietary Hsp90 inhibitor compound (OS47720) not only elicits a heat-shock-like response but also offers synaptic protection in symptomatic Tg2576 mice, a model of Alzheimer's disease, without noticeable systemic toxicity. Despite a short half-life of OS47720 in mouse brain, a single intraperitoneal injection induces rapid and long-lasting (>3 days) nuclear activation of the heat-shock factor, HSF1. Mechanistic study indicates that the remedial effects of OS47720 depend upon HSF1 activation and the subsequent HSF1-mediated transcriptional events on synaptic genes. Taken together, this work reveals a novel role of HSF1 in synaptic function and memory, which likely occurs through modulation of the synaptic transcriptome.

SUBMITTER: Wang B 

PROVIDER: S-EPMC5323357 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

A CNS-permeable Hsp90 inhibitor rescues synaptic dysfunction and memory loss in APP-overexpressing Alzheimer's mouse model via an HSF1-mediated mechanism.

Wang B B   Liu Y Y   Huang L L   Chen J J   Li J J JJ   Wang R R   Kim E E   Chen Y Y   Justicia C C   Sakata K K   Chen H H   Planas A A   Ostrom R S RS   Li W W   Yang G G   McDonald M P MP   Chen R R   Heck D H DH   Liao F-F FF  

Molecular psychiatry 20160726 7


Induction of neuroprotective heat-shock proteins via pharmacological Hsp90 inhibitors is currently being investigated as a potential treatment for neurodegenerative diseases. Two major hurdles for therapeutic use of Hsp90 inhibitors are systemic toxicity and limited central nervous system permeability. We demonstrate here that chronic treatment with a proprietary Hsp90 inhibitor compound (OS47720) not only elicits a heat-shock-like response but also offers synaptic protection in symptomatic Tg25  ...[more]

Similar Datasets

2019-01-30 | GSE125850 | GEO
| S-EPMC5607468 | biostudies-literature
| S-EPMC4176764 | biostudies-literature
| S-EPMC5841141 | biostudies-other
| S-EPMC6391616 | biostudies-literature
| S-EPMC5605817 | biostudies-other